Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular plating for targetry: proof of concept using <sup>nat</sup>Gd(p,x)<sup>155</sup>Tb cross section measurements.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2026
Same author

Experimental and simulated <math><semantics><mrow><msub><mi>H</mi> <mn>2</mn></msub> <msub><mi>O</mi> <mn>2</mn></msub></mrow> <annotation>${{{\mathrm{H}}}_2}{{{\mathrm{O}}}_2}$</annotation></semantics></math> in pure water under conventional and ultra-high dose rates for single pulse proton irradiation.

Medical physics·2026
Same author

<sup>211</sup>At targeted alpha therapy in Europe: overcoming clinical, regulatory, and infrastructure challenges.

European journal of nuclear medicine and molecular imaging·2026
Same author

FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Blood advances·2026
Same author

Optimal acquisition time of [<sup>68</sup>Ga]Ga-PentixaFor PET/CT for initial staging of multiple myeloma: an ancillary study to the PentiMyelo protocol.

EJNMMI research·2026
Same author

Unveiled Impact of <sup>211</sup>At-Labeled Compounds' Ability to Form Halogen Bonds on Their <i>In Vivo</i> Stability.

ACS physical chemistry Au·2026

Related Experiment Video

Updated: Apr 17, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K

Tumor immunotargeting using innovative radionuclides.

Françoise Kraeber-Bodéré1,2,3, Caroline Rousseau4,5, Caroline Bodet-Milin6,7

  • 1Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Inserm UMR 892, CNRS UMR 6299, Nantes 44007, France. francoise.bodere@chu-nantes.fr.

International Journal of Molecular Sciences
|February 14, 2015
PubMed
Summary
This summary is machine-generated.

Antibodies targeting radionuclides offer new hope for cancer imaging and therapy. Advances in radionuclides and antibody strategies are paving the way for personalized medicine and improved treatments for various cancers.

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

10.2K

Related Experiment Videos

Last Updated: Apr 17, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.7K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.5K
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
10:48

PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator

Published on: December 28, 2017

10.2K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Immunotherapy

Background:

  • Radiolabeled antibodies have long been explored for cancer diagnosis and treatment.
  • Limited clinical adoption has been observed despite extensive research.

Purpose of the Study:

  • To review recent advancements in antibody-based radionuclide targeting for cancer.
  • To highlight new radionuclides and strategies enhancing tumor imaging and therapy.

Main Methods:

  • Review of current literature on radiolabeled antibodies.
  • Analysis of emerging radionuclides (e.g., 177Lu, 67Cu, alpha-emitters) and PET imaging agents (e.g., 68Ga, 18F, 64Cu, 124I, 89Zr).
  • Evaluation of novel antibody analogues and pretargeting strategies.

Main Results:

  • New radionuclides offer improved physical properties for targeted therapy and imaging.
  • Positron Emission Tomography (PET) with various radionuclides provides new avenues for immuno-specific tumor imaging.
  • Advanced antibody designs and pretargeting techniques significantly boost immunotargeting efficacy.

Conclusions:

  • Emerging radionuclides and advanced antibody strategies are revitalizing antibody-based cancer theranostics.
  • These developments are crucial for personalized medicine, companion diagnostics, and effective cancer treatment.
  • The integration of imaging and therapy holds significant promise for both hematological malignancies and solid tumors.